OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Treatment With Liposomal Irinotecan Plus Fluorouracil and Leucovorin for Patients With Previously Treated Metastatic Biliary Tract Cancer
Jaewon Hyung, Il Hwan Kim, Kyu‐pyo Kim, et al.
JAMA Oncology (2023) Vol. 9, Iss. 5, pp. 692-692
Closed Access | Times Cited: 42
Jaewon Hyung, Il Hwan Kim, Kyu‐pyo Kim, et al.
JAMA Oncology (2023) Vol. 9, Iss. 5, pp. 692-692
Closed Access | Times Cited: 42
Showing 1-25 of 42 citing articles:
Immunotherapy in Biliary Tract Cancers: Current Standard-of-Care and Emerging Strategies
Justin H. Lo, Rajiv Agarwal, Laura W. Goff, et al.
Cancers (2023) Vol. 15, Iss. 13, pp. 3312-3312
Open Access | Times Cited: 24
Justin H. Lo, Rajiv Agarwal, Laura W. Goff, et al.
Cancers (2023) Vol. 15, Iss. 13, pp. 3312-3312
Open Access | Times Cited: 24
Nanoliposomal irinotecan and fluorouracil plus leucovorin versus fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based therapies (AIO NALIRICC): a multicentre, open-label, randomised, phase 2 trial
Arndt Vogel, Anna Saborowski, Patrick Wenzel, et al.
The Lancet. Gastroenterology & hepatology (2024) Vol. 9, Iss. 8, pp. 734-744
Open Access | Times Cited: 14
Arndt Vogel, Anna Saborowski, Patrick Wenzel, et al.
The Lancet. Gastroenterology & hepatology (2024) Vol. 9, Iss. 8, pp. 734-744
Open Access | Times Cited: 14
Biliary tract cancers: French national clinical practice guidelines for diagnosis, treatments and follow-up (TNCD, SNFGE, FFCD, UNICANCER, GERCOR, SFCD, SFED, AFEF, SFRO, SFP, SFR, ACABi, ACHBPT)
Gaël S. Roth, Loïc Verlingue, Matthieu Sarabi, et al.
European Journal of Cancer (2024) Vol. 202, pp. 114000-114000
Open Access | Times Cited: 8
Gaël S. Roth, Loïc Verlingue, Matthieu Sarabi, et al.
European Journal of Cancer (2024) Vol. 202, pp. 114000-114000
Open Access | Times Cited: 8
New systemic treatment paradigms in advanced biliary tract cancer and variations in patient access across Europe
Lorenza Rimassa, Ángela Lamarca, Grainne M. O’Kane, et al.
The Lancet Regional Health - Europe (2025) Vol. 50, pp. 101170-101170
Open Access | Times Cited: 1
Lorenza Rimassa, Ángela Lamarca, Grainne M. O’Kane, et al.
The Lancet Regional Health - Europe (2025) Vol. 50, pp. 101170-101170
Open Access | Times Cited: 1
Intrahepatic cholangiocarcinoma: Evolving strategies in management and treatment
Maria Consiglia Bragazzi, Rosanna Venere, Emanuela Ribichini, et al.
Digestive and Liver Disease (2023) Vol. 56, Iss. 3, pp. 383-393
Closed Access | Times Cited: 16
Maria Consiglia Bragazzi, Rosanna Venere, Emanuela Ribichini, et al.
Digestive and Liver Disease (2023) Vol. 56, Iss. 3, pp. 383-393
Closed Access | Times Cited: 16
Current Standards, Multidisciplinary Approaches, and Future Directions in the Management of Extrahepatic Cholangiocarcinoma
Margaret Wheless, Rajiv Agarwal, Laura W. Goff, et al.
Current Treatment Options in Oncology (2024) Vol. 25, Iss. 1, pp. 127-160
Open Access | Times Cited: 7
Margaret Wheless, Rajiv Agarwal, Laura W. Goff, et al.
Current Treatment Options in Oncology (2024) Vol. 25, Iss. 1, pp. 127-160
Open Access | Times Cited: 7
Unresectable biliary tract cancer: Current and future systemic therapy
Danmei Zhang, Klara Dorman, C. Benedikt Westphalen, et al.
European Journal of Cancer (2024) Vol. 203, pp. 114046-114046
Open Access | Times Cited: 7
Danmei Zhang, Klara Dorman, C. Benedikt Westphalen, et al.
European Journal of Cancer (2024) Vol. 203, pp. 114046-114046
Open Access | Times Cited: 7
Management of Intrahepatic Cholangiocarcinoma: A Narrative Review
Carolyn Tsung, Patrick L. Quinn, Aslam Ejaz
Cancers (2024) Vol. 16, Iss. 4, pp. 739-739
Open Access | Times Cited: 5
Carolyn Tsung, Patrick L. Quinn, Aslam Ejaz
Cancers (2024) Vol. 16, Iss. 4, pp. 739-739
Open Access | Times Cited: 5
NALIRIFOX for metastatic pancreatic adenocarcinoma: hope or hype?
Christopher Nevala-Plagemann, Ignacio Garrido‐Laguna
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 8, pp. 567-568
Closed Access | Times Cited: 5
Christopher Nevala-Plagemann, Ignacio Garrido‐Laguna
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 8, pp. 567-568
Closed Access | Times Cited: 5
Serum 25‐Hydroxyvitamin D Levels and Survival Outcomes in Advanced Biliary Tract Cancer: Results From the NIFTY Trial
So Heun Lee, Jaekyung Cheon, Il Hwan Kim, et al.
Cancer Medicine (2025) Vol. 14, Iss. 1
Open Access
So Heun Lee, Jaekyung Cheon, Il Hwan Kim, et al.
Cancer Medicine (2025) Vol. 14, Iss. 1
Open Access
Observational Study of Best Supportive Care With or Without Oral Capecitabine in Patients With Metastatic Gallbladder Carcinoma at a Tertiary Center in India
Abhinav Srivastava, Shagun Misra, Neeraj Rastogi, et al.
JCO Global Oncology (2025), Iss. 11
Closed Access
Abhinav Srivastava, Shagun Misra, Neeraj Rastogi, et al.
JCO Global Oncology (2025), Iss. 11
Closed Access
The efficacy of second‐line chemotherapy for advanced biliary tract cancer: A systematic review and network meta‐analysis
Inhwan Hwang, Sang‐Ah Han, Ji Hun Jeong, et al.
Journal of Hepato-Biliary-Pancreatic Sciences (2025)
Closed Access
Inhwan Hwang, Sang‐Ah Han, Ji Hun Jeong, et al.
Journal of Hepato-Biliary-Pancreatic Sciences (2025)
Closed Access
PLGA Polymers and Doxorubicin for the Treatment of Malignant Gliomas in Adults: An Overview
V. V. Kudelkina, Andrey D. Gerasimov, А. М. Косырева, et al.
The Open Medicinal Chemistry Journal (2025) Vol. 19, Iss. 1
Open Access
V. V. Kudelkina, Andrey D. Gerasimov, А. М. Косырева, et al.
The Open Medicinal Chemistry Journal (2025) Vol. 19, Iss. 1
Open Access
Advancements in Locoregional Therapies for Unresectable Intrahepatic Cholangiocarcinoma
C. O'Donnell, Umair Majeed, Michael Rutenberg, et al.
Current Oncology (2025) Vol. 32, Iss. 2, pp. 82-82
Open Access
C. O'Donnell, Umair Majeed, Michael Rutenberg, et al.
Current Oncology (2025) Vol. 32, Iss. 2, pp. 82-82
Open Access
Update for: New developments in systemic therapy for advanced biliary tract cancer
Chigusa Morizane, Makoto Ueno, Masafumi Ikeda, et al.
Japanese Journal of Clinical Oncology (2025)
Closed Access
Chigusa Morizane, Makoto Ueno, Masafumi Ikeda, et al.
Japanese Journal of Clinical Oncology (2025)
Closed Access
Molecular subtypes of intrahepatic cholangiocarcinoma
A. De Santis, Lei Zhu, Jianxin Tao, et al.
Trends in Molecular Medicine (2025)
Open Access
A. De Santis, Lei Zhu, Jianxin Tao, et al.
Trends in Molecular Medicine (2025)
Open Access
How I Treat Advanced Biliary Cancer
Arathi Mohan, Vaibhav Sahai
Advances in Oncology (2025)
Closed Access
Arathi Mohan, Vaibhav Sahai
Advances in Oncology (2025)
Closed Access
Eastern Canadian Gastrointestinal Cancer Consensus Conference 2024
Jennifer Leigh, Atique U. Ahmed, F. Aubin, et al.
Current Oncology (2025) Vol. 32, Iss. 3, pp. 175-175
Open Access
Jennifer Leigh, Atique U. Ahmed, F. Aubin, et al.
Current Oncology (2025) Vol. 32, Iss. 3, pp. 175-175
Open Access
Liposomal irinotecan for previously treated patients with biliary tract cancer: A pooled analysis of NIFTY and NALIRICC trials
Changhoon Yoo, Anna Saborowski, Jaewon Hyung, et al.
Journal of Hepatology (2025)
Open Access
Changhoon Yoo, Anna Saborowski, Jaewon Hyung, et al.
Journal of Hepatology (2025)
Open Access
Current Status of Targeted Therapy for Biliary Tract Cancer in the Era of Precision Medicine
Takafumi Mie, Takashi Sasaki, Takeshi Okamoto, et al.
Cancers (2024) Vol. 16, Iss. 5, pp. 879-879
Open Access | Times Cited: 3
Takafumi Mie, Takashi Sasaki, Takeshi Okamoto, et al.
Cancers (2024) Vol. 16, Iss. 5, pp. 879-879
Open Access | Times Cited: 3
Recent Advances in Systemic Therapy for Advanced Intrahepatic Cholangiocarcinoma
Changhoon Yoo, Jaewon Hyung, Stephen L. Chan
Liver Cancer (2023) Vol. 13, Iss. 2, pp. 119-135
Open Access | Times Cited: 8
Changhoon Yoo, Jaewon Hyung, Stephen L. Chan
Liver Cancer (2023) Vol. 13, Iss. 2, pp. 119-135
Open Access | Times Cited: 8
Targeted Therapies in Advanced Cholangiocarcinoma
Michael H. Storandt, Peter C. Kurniali, Amit Mahipal, et al.
Life (2023) Vol. 13, Iss. 10, pp. 2066-2066
Open Access | Times Cited: 7
Michael H. Storandt, Peter C. Kurniali, Amit Mahipal, et al.
Life (2023) Vol. 13, Iss. 10, pp. 2066-2066
Open Access | Times Cited: 7
Efficacy and biomarker analysis of second‐line nab‐paclitaxel plus sintilimab in patients with advanced biliary tract cancer
Xiaofen Li, Nan Zhou, Yang Yu, et al.
Cancer Science (2024) Vol. 115, Iss. 7, pp. 2371-2383
Open Access | Times Cited: 2
Xiaofen Li, Nan Zhou, Yang Yu, et al.
Cancer Science (2024) Vol. 115, Iss. 7, pp. 2371-2383
Open Access | Times Cited: 2
BilT03: Phase 1b/2 multicenter trial of nivolumab with 5-fluorouracil and liposomal irinotecan for previously treated advanced biliary tract cancer
Vaibhav Sahai, Kent A. Griffith, Bruce Lin, et al.
Med (2024), pp. 100547-100547
Closed Access | Times Cited: 2
Vaibhav Sahai, Kent A. Griffith, Bruce Lin, et al.
Med (2024), pp. 100547-100547
Closed Access | Times Cited: 2
Curcumin-loaded graphene oxide quantum dots enhance otoprotective effects via blocking cuproptosis
An Hu, Jianwei Zhang, Liyun Yang, et al.
Frontiers in Bioengineering and Biotechnology (2023) Vol. 11
Open Access | Times Cited: 5
An Hu, Jianwei Zhang, Liyun Yang, et al.
Frontiers in Bioengineering and Biotechnology (2023) Vol. 11
Open Access | Times Cited: 5
